Actionable news
All posts from Actionable news
Actionable news in ZGNX: Zogenix, Inc.,

On October

The FDAs specific information requests are related to normative ranges for echocardiograms being conducted during the course of the pediatric Phase 3 program and an amended Phase 3 study protocol to reflect a required follow-up echocardiogram three to six months after patients discontinue treatment with ZX008. Zogenix responded with the requested information required to initiate the clinical program, and the expected ZX008 clinical development timeline remains unchanged, including the expectation that the Phase 3 program will begin in the fourth quarter of 2015.

Zogenix cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. Words such as believes, indicates, will, plans, designed and simil ar expressions are intended to identify forward-looking statements. These statements are based on Zogenixs current beliefs and expectations. These...